Adjust Text Size:
Browse Clinical Trials
Join the Email List
Sign up for our email bulletin
Participant Stories
“I participate because it is the right thing to do, for myself, for my children, and for the millions of people who have Parkinson’s disease. Without participation there will be no cure.” –Mike, Diagnosed 7 years
Recently Diagnosed with Parkinson's Disease?
If you have recently been diagnosed with Parkinson’s disease (PD) understanding the disease, and learning about the resources available to you, are good first steps.
Rehabilitation of Everyday Memory Impairment in Parkinson’s Disease (REMI-PD)
Official Study Title: Rehabilitation of Everyday Memory Impairment in Parkinson’s Disease: A Pilot Study
Sponsor: Washington University in St. Louis School of Medicine
Clinicaltrials.gov ID: NCT01469741
Study ID: REMI-PD
Summary
Cognitive CognitiveRelated to mental activities having to do with perception, memory, judgment, and reasoning. impairment is common among individuals with Parkinson’s disease (PD) who do not have dementia DementiaA decline in higher-level brain functions, such as memory, reasoning and personality. and is a significant source of disability and reduced quality of life. Unfortunately, there are no successful interventions to address these impairments. Impairment of prospective memory (remembering to perform a planned action) is a particularly functionally and clinically relevant problem in PD. The investigator's project will determine if a targeted intervention strategy improves PD participants' prospective memory. The investigator's goal is to improve PD patients' everyday prospective memory so they can successfully perform desired activities and roles.
Study Phase
Phase 1
What is a study phase?
Symptoms Addressed: Non-movement Symptoms
Memory
Time Commitment
- Less than six months
- There are three study visits over six weeks. The first visit is three hours. The second visit, one week after the first visit, is two hours. The third visit is one month after the second visit and lasts two hours.
Eligibility
- Minimum Age: 50
- Gender(s) Accepted: Either
Inclusion Criteria
- Diagnosis of idiopathic IdiopathicOf, relating to, or designating a disease having no known cause. typical PD
- Treatment of levodopa/ LevodopaA compound that is converted into dopamine (the brain chemical which is deficient in people with Parkinson's) in the brain. carbidopa. CarbidopaDrug given in combination with levodopa to ensure that more of the latter reaches the brain and changes into dopamine, rather than being broken down in the bloodstream. This allows for lower doses of levodopa to be used, reducing the risk of nausea, vomiting, and other side effects.
Exclusion Criteria
- Possible dementia.
- Treatment with certain medications that interfere with cognition (e.g., anticholinergics),
- Change in medications over the study period, other neurological disorders, brain surgery (e.g., STN DBS).
- History of psychotic disorder or significant current psychiatric disorder, or any condition that would interfere with testing (e.g., vision problems).
Enrollment
Expected Enrollment: 66 (US)
Date Enrollment Began: Jun 2011
Date Enrollment Ends: Dec 2015
Last Updated Date: Jan 24 2012
Trial Post Date: Jan 24 2012
Website: http://www.clinicaltrials.gov/ct2/show/NCT01469741
Primary Contacts and Locations
Missouri
- Tasha Doty, M.A. — Study Coordinator
Washington University in St. Louis School of Medicine
dotyt@npg.wustl.edu
Phone: (314) 362-7160
4525 Scott Ave, Campus Box 8134
St. Louis, MO 63110
USA - Erin Foster, OTD, OTR/L — Primary Investigator
University in St. Louis School of Medicine
erfoster@wustl.edu
Phone: (314) 286-1638
600 S. Euclid, Campus Box 8111
St. Louis, MO 63110
USA
